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Abstract
Mucin genes encode a family of the largest expressed proteins in the human genome. The proteins
are highly substituted with O-linked oligosaccharides which greatly restrict access to the peptide
backbones. The genomic organization of the N-terminal, O-glycosylated, and C-terminal regions
of most of the mucins has been established and is available in the sequence databases. However,
much less is known about the fate of their exposed protein regions after translation and secretion,
and, to date, detailed proteomic studies complementary to the genomic studies are rather limited.
Using mucins isolated from cultured human airway epithelial cell secretions, trypsin digestion and
mass spectrometry, we investigated the proteome coverage of the mucins responsible for the
maintenance and protection of the airway epithelia. Excluding the heavily glycosylated mucin
domains, up to 85% coverage of the N-terminal region of the gel forming mucins MUC5B and
MUC5AC was achieved, and up to 60% of the C-terminal regions were covered, suggesting that
more N- and sparsely O-glycosylated regions as well as possible other modifications are available
at the C-terminus. All possible peptides from the cysteine-rich regions that interrupt the heavily
glycosylated mucin domains were identified. Interestingly, 43 cleavage sites from ten different
domains of MUC5B and MUC5AC were identified, which possessed a non-tryptic cleavage site
on the N-terminal end of the peptide, indicating potential exposure to proteolytic and/or
“spontaneous cleavages”. Some of these non-tryptic cleavages may be important for proper
maturation of the molecule, before and/or after secretion. Most of the peptides identified from
MUC16 were from the SEA region. Surprisingly, three peptides were clearly identified from its
heavily glycosylated regions. Up to 25% coverage of MUC4 was achieved covering seven
different domains of the molecule. All peptides from the MUC1 cytoplasmic domain were
detected along with the three non-tryptic cleavages in the region. Only one peptide was identified
from MUC20 which led us to successful antisera raised against the molecule. Taken together, this
report represents our current efforts to dissect the complexities of mucin macromolecules.
Identification of regions accessible to proteolysis can help in the design of effective antibodies and
points to regions that might be available for mucin-protein interactions and identification of
cleavage sites will enable understanding of their pre- and post-secretory processing in normal and
disease environments.
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Mucins are high molecular weight glycoproteins that are physically large in size, as well as
high in mass. At least 20 mucin genes have been identified to date. At least ten human
mucin genes (membrane tethered mucins MUC1, 4, and 16, and the gel forming mucins
MUC5AC, 5B, as well as others not so well characterized in the airways e.g. MUCs 2, 7, 13,
15, 19 and 20) have been observed at the mRNA level in lung tissue from healthy
individuals 1, 2. In a previous report, we identified five of these mucin gene products using
proteomic approaches on mucus harvested from primary human epithelial cell culture
secretions, and induced sputum3. The five identified mucins were the gel forming mucins
MUC5AC and MUC5B and the membrane mucins MUC1, MUC4 and MUC16. MUC20
was not reported because it is a relatively new member of the mucin family and its sequence
was not available in the databases at the time of the publication.
The so called gel-forming mucins are essential for the formation of a flowing mucus gel
vital for epithelial protection and lung function. In healthy lungs, MUC5B is mostly
produced by mucous cells in the sub-mucosal glands4 while MUC5AC is produced by
airway surface goblet cells 5. In disease 6 and airway epithelial cell cultures 7, however,
MUC5B is produced by surface goblet cells as well. The other three well-characterized
mucins all belong to the transmembrane family; MUC1 is most strongly identified with the
microvilli, while MUC4 appears to be strongly associated with the cilia 8. MUC16 is more
mysterious, as it is strongly associated with MUC5B secreting cells in the sub-mucosal
glands; however, in cell culture, it is expressed in goblet cells 8, which secrete MUC5B,
predominantly. Both gel forming and membrane related mucins of the respiratory tract
function as part of the airway’s innate defense system by enabling the capture and
elimination of particulates and pathogens by mucociliary transport and/or cough clearance.
As a protein product of MUC genes, mucins show complex multi-domain structures. For
example, the large gel forming mucins have at least two serine, threonine, proline (STP)
rich, heavily glycosylated mucin domains (MD) with small cysteine-rich compartments
localized within these domains as well as two to four Von Willebrand Factor (vWF) like
domains situated at the N- and C- terminal regions 9,10. Membrane related mucins of the
airways also show complexity by displaying multi domain structures such as VNTR
(variable number of tandem repeats), O-glycan rich domains, N-glycosylated regions,
cysteine-rich regions, SEA regions, and transmembrane, and cytoplasmic domains 1, 11, 12.
Membrane tethered mucins can also be found as secreted soluble forms released from the
cell surface after protein cleavage or, alternatively, as spliced secreted forms sometimes
lacking their distinctive glycosylated domains. The identification of the gene sequences of
these molecules has now been achieved and the genomic organization of N-terminal, O-
glycosylated mucin domains and C-terminal regions of MUC5B and MUC5AC has been
well characterized 9, 10 and is available in sequence databases. However, much less is known
about the state form and function of the naked protein regions themselves, and proteomic
studies complementary to the genomic information are rather limited. Information such as
the naked protein regions accessible and/or inaccessible to proteolytic cleavages, cleavage
products, and post translational modifications are all crucial to understanding the three
dimensional protein structure and structure/function relationships. This information is also
important for the practical purpose of producing effective antibodies, to reveal interaction
sites and understanding more about their biological roles in health and in the progression of
chronic airway diseases. For these reasons, we have undertaken a major proteomic study of
airway mucins and now report the most detailed peptide coverage available, which promises
to advance our understanding of these large and complex macromolecules.
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Two different airway cell culture systems that secrete mucus were used in this study as a
source of mucins: human tracheobronchial epithelial cells (HTBE) and airway epithelial
Calu-3 cells. HTBE cells in cultures produces more MUC5B than MUC5AC (up to 10-
fold) 13. Additionally, HTBE cells are a good source for membrane tethered mucins 3.
Previous studies suggest that Calu-3 cells are enriched for goblet (mucous) cells 14 and our
unpublished studies indicate that these cells produce more MUC5AC than MUC5B (up to 5
fold). For this reason, HTBE secretions were used as a source of MUC5B as well as all
membrane tethered mucins and Calu-3 secretions were used for MUC5AC coverage in this
report. HTBE cells were obtained from airway specimens resected from normal donor tissue
from the University of North Carolina (UNC) lung transplant program or from NDRI
(National Disease Research Interchange) under UNC Institutional Review Board-approved
protocols. Primary airway epithelial cells were isolated by the UNC Cystic Fibrosis (CF)
Center Tissue Culture Core and expanded on plastic to generate passage 1 cells and plated at
a density of 600 k cells per well on permeable Transwell-Col (T-Col, 24 mm diameter)
supports. Human tracheobronchial epithelia (HTBE) cultures were generated by provision of
an air-liquid interface for 4–6 weeks to form well-differentiated, polarized cultures that
resemble in vivo pseudo-stratified mucociliary epithelium15. Airway epithelial Calu-3 cells
were derived from pleural effusion associated with a human lung adenocarcinoma. Calu-3
cells were grown on 12-mm Transwell supports (Corning) and maintained at air–liquid
interface for at least three weeks, as previously described14. Mucus secretions from both cell
cultures were obtained by incubating 1 ml of PBS on the apical surface of HTBE and Calu-3
cultures for 30 min at 37°C, removing the PBS with a large caliber pipette and then
repeating the procedure one time. The 2 ml of diluted mucus secretions obtained per culture
were pooled and placed immediately on ice until solubilization with solid GuHCl to make
4M solution..
Sample preparation
Mucin samples were prepared as previously described3. Briefly, collected secretion material
was originally in PBS. An appropriate amount of solid GuHCl was then added to that
material to make a 4M GuHCl solution, then CsCl was added to a density of 1.45 g/ml.
Isopycnic density-gradient centrifugation was performed for 60 h at 36000 rpm on a
Beckman L8-M ultracentrifuge using 50.2TI, 12 × 40 ml rotor. The sample was unloaded as
2 ml fractions from the top and then analyzed for PAS staining, antibody, and density. PAS-
rich fractions (8–13) were pooled as the mucin rich fraction. High density regions (fractions
14–20) were pooled and analyzed separately as MUC4 and MUC16 rich regions. The pools
were reduced by adding 10 mM dithiothreitol (DTT) to each sample for 2–3 h at 37°C. Free
thiols were subsequently alkylated by the addition of 30 mM iodoacetamide for 1 h in the
dark at ambient temperature. 1.5 ml of the reduced and alkylated samples was subjected to a
HiTrap Desalting column (Sephadex G-25, Amersham Biosciences) to exchange the buffer
to 50 mM ammonium hydrogen carbonate (NH4HCO3). Two ml of eluents were collected.
0.5 μg modified trypsin (proteomics grade, Sigma) was added to samples then incubated 18
h at 37°C. Three independent digests of the same pool were prepared. Tryptic digests
(peptides and glycopeptides) were chromatographed on an Amersham Biosciences Superdex
200 HR 10/30 column using Ettan LC (Amersham Pharmacia Biotech) chromatographic
equipment. The column was eluted with 50 mM NH4HCO3 at a flow rate of 0.3 ml/min. The
void (large glycopeptides) and the including (peptides) volume were collected separately.
The peptide pool was dried down ten times by volume using a Heto vacuum concentrator
and samples were mixed 1:1 with 1% formic acid and then subjected to nano-LC-MS/MS
analysis. To determine N- glycosylation sites, an aliquot from the reduced and alkylated
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pools was incubated with PNGase F (Sigma) for 60 minutes at 37°C and subjected to
digestion as described above (digest #3).
Mass Spectrometry/Electrospray LC-MS/MS
Digested samples (2μL) were introduced via a Waters nanoACQUITY UPLC system. The
analytical system was attached directly to the Z spray source and was configured with a
PepMap™ C18 (LC Packing, 300Nm ID × 5mm) pre-concentration column in series with an
Atlantis® (Waters) dC18 NanoEase™ (75 m x 150 mm) nanoscale analytical column. The
spray tip used was PicoTip™ (New objectives USA) capillary with 10 μm diameter. The
pump was programmed to deliver 0.4 μL/min, through the analytical column. Samples were
separated on the column with a gradient of 5% acetonitrile in 0.1% formic acid to 60 %
acetonitrile in 0.1% formic acid over 120 min. The composition of the solvents A, B and C
was 5% (v/v) ACN in 0.1% (v/v) formic acid, 95% (v/v) ACN in 0.1% (v/v) formic acid and
0.1% (v/v) formic acid, respectively. All data were acquired using Waters Q-Tof micro,
hybrid quadropole orthogonal acceleration time-flight mass spectrometer (Waters,
Manchester, UK) with MassLynx 4.1 software. The mass spectrometer data directed
analysis (DDA) acquired MS survey data from m/z 200 to 1500 with the criteria for MS to
MS/MS including ion intensity and charge state using a one second MS survey scan
followed by 1.5 second MS/MS scans, each on three different precursor ions. The Q-Tof
micro was programmed to ignore any singly charged species and the collision energy used
to perform MS/MS was carried out according to the mass and charge state of the eluting
peptide. Precursors detected were excluded from any further MS/MS experiment for 180
seconds. All analyses were repeated three times for each sample, and peptides identified in
the first run were excluded from the second analysis.
Data processing and database searching
The raw data acquired were processed using the ProteinLynx module of MassLynx 4.0 to
produce *.pkl (peaklist) files which are suitable for the MS/MS ions database search via
search engines. The peptide QA filter was 30 to eliminate poor quality spectra and the
minimum peak width at half height was set to four to eliminate background noise peaks.
Smoothing (x2 Savitzky Golay) and polynomial fitting were performed on all peaks and the
centroid taken at 80% of the peak height. The processed data was searched against the
National Center for Biotechnology Information (NCBI) non-redundant (nr) protein database
(version 2011-09-12: 15,270,974 sequences, 4,841,198 Homo sapiens sequences) and
Swiss-Prot (version 2011-09-21: 532,146 sequences, 20,249 Homo sapiens sequences) using
the in-house MASCOT (Matrix Science, UK) search engine (Version 2.0). Parameters used
for the MASCOT search were: Taxonomy human, 0.2 Da mass accuracy for parent ions and
0.3 Da mass accuracy for fragment ions, one missed cleavage was allowed, and
carbomidomethyl-Cys and methionin oxidation were used as fixed and variable
modifications, respectively. MASCOT probability-based Mowse individual ion scores > 40
were accepted as indicating identity or extensive homology (p<0.05). MS/MS spectrum
scores between 20–40 were examined individually with the acceptance criteria that the
parent and fragment ion masses were within the calibrated tolerance limits and that the
spectrum contained an extended series of consecutive y- or b- ions.
Detecting half/non-tryptic peptides
A Mascot “error tolerant” search was performed to examine unmatched spectra resulting
from non-tryptic/non-specific cleavages, mass measurement error, incorrect determination
of precursor charge, unsuspected chemical & post-translational modifications, and other
factors. No cleavage enzyme is specified in this stage of search, thereby allowing peptides
originating from unexpected enzyme activity or self cleavage of the molecule to be
identified.
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Peptide coverage analysis of MUC5B
The MUC5B apoprotein (Swiss-Prot Accession # Q9HC84) has a large monoisotopic mass
of 588,003 Da and yields 293 theoretical tryptic cleavage sites (ExPasy-PeptideCutter). The
MD region has 79 tryptic peptides, all of which are heavily glycosylated. No peptides were
identified from the MD region and the size of the glycopeptides recovered (Mw 0.1 MDa to
1 MDa) suggests that none of the potentially cleavable sites in the region could be accessed.
Excluding the large central mucin domains where extensive glycosylation limits access by
trypsin, about 181 of these are detectable by mass spectrometry of which 109 were
successfully identified from 17 different regions of the protein (table 1, supplementary data
1). From the N-terminus, 52 of the 67 predicted tryptic peptides (85% coverage) were
identified. All of the 35 predicted peptides from seven cysteine-rich regions inside the MD
region were successfully identified. Of 34 peptides identified in the C-terminus, 22 (60%
coverage) were identified. Some 35 peptides are composed of one to five amino acid
residues, while eight peptides outside the MD region are larger than 5000 Da in mass, with
five of these eight peptides having potential O-glycosylation sites (NetOGlyc 3.1:
http://www.cbs.dtu.dk/services/NetOGlyc). The range of our acquisition was between 150–
2000 m/z during a survey scan and 100–1500 m/z in the MS/MS mode; therefore, this
acquisition was appropriate for the detection of peptides of up to 6000 m/z in mass
employing triply charged peptides and 4000 for the doubly charged. Peptides that were
smaller than approximately five amino acid residues were not within our accurate range of
peptide identification.
The mature, fully glycosylated, MUC5B protein is relatively low in putative N-glycosylation
sites and most of these are outside the MD region. Whether they are occupied is not clear.
The C-terminus of the molecule has 12 putative N-glycosylation sites (NetNGlyc 1.0 Server:
http://www.cbs.dtu.dk/services/NetNGlyc/), while only four putative N-glycosylation sites
are available at the N-terminus. Only one extra peptide from the N-terminal
region, 200YANQTCGLCGDFNGLPAFNEFYAHNAR225, and two peptides from the C-
terminal region, 5208LPYSLFHNNTEGQCGTCTNNQR5229
and 5036VVLLDPKPVANVTCVNK5552 were identified after PNGase-F treatment which
cleaves the N-linked glycans on the protein, which were consistent with this particular mode
of glycosylation. Absence of other putative N-glycosylated peptides by PNGase F suggests
that those peptides could be modified in some other way. Another putative site of
glycosylation on mucins is mannosylation of the first tryptophan residue of the WXXW
motif 16, called C-mannosylation. Each of the cysteine-rich domains contains one WXXW
motif; however, all three predicted tryptophan mannosylation sites in the first three cysteine-
rich domains were identified without any deglycosylation pre-processing. These peptides
were 1340WSSWYNGHR1348, 1507CQWTEWFDEDYPK1520, and 1787CEWTEWFDV…
ENIR1534. Our observations indicate that those peptides were available for mass
spectrometry identification without any modification, though it is not possible to rule out the
presence of this modification at a low level. The other four predicted C-mannosylation sites
are on peptides partly inside the MD/VNTR region but stretching some way into cysteine-
rich domains four-seven. The N-terminal part of these peptides could be heavily
glycosylated and thus, their identification would not be possible with our standard methods.
Cysteine subdomains (Cys1-Cys7) that interrupt the highly O-glycosylated MD regions
consist of 108 amino acid residues, each containing ten cysteine residues in which
intramolecular disulfide bonds can be formed. The functional significance of these regions
in the middle of heavily glycosylated regions is still speculative, but a recent suggestion is
that the CysD domains of MUC2 mucin might serve as non-covalent cross-links in the
colonic mucus gel 17. Large portions of the heavily glycosylated regions are present both
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upstream and downstream of these cysteine-rich regions. We identified almost all
technically suitable peptides from all cysteine-rich regions indicating the reduction process
was suitable for breaking all of the disulfide bonds in these regions, thus making them
accessible to proteases. Taken together, we have 30% coverage of the mature glycosylated
MUC5B. However, after subtracting non-accessible heavily glycosylated MD regions, the
O- and/or N-glycosylated regions and the tryptic fragments unidentifiable for technical
reasons of the mass spectrometry, we cover the molecule up to 95 percent. Only five percent
of the other readily identifiable peptides were missed from our exhaustive analysis, the
majority of which were from the N-terminus. The inability to achieve 100 percent coverage
suggests that the access of trypsin is restricted in some portions of the N- and C- terminal
regions by other post-translational modifications. A previous study reported peptide
coverage of MUC5B isolated from saliva. Using mass spectrometry, they identified 84
peptides from different domains of MUC5B 18.
Unexpectedly, we found 27 non-tryptic cleavage sites from MUC5B, 16 of which were from
the N-terminal region (table 4). In particular, four cleavage site were from inside the vWFD
domains, ten from the unique region, one from the TIL region, and one from the
MUC11p15-type region. 204CGLCG208 and 1023CGLCG1027 repeat sequence in both vWD1
and vWD3 regions are highly conserved in secreted mucins and have been proposed to be
essential for mutimerization at low pH in the trans-Golgi 19. Interestingly, one of the
cleavage sites we identified was at the D1 domain and divides the CGLCG disulfide
isomerase catalytic site (YANQTCGL//1026CGDFNGL……YAHNAR1044). More
interestingly, the sequence immediately upstream of the cleavage has a putative N-
glycosylation (…NQT…) site; this cleavage site could be detected only after PNGase F
treatment, suggesting possible protection of this multimerization site by N-glycosylation.
We also found three different cleavage sites inside the Cys-rich regions: the VL//
CCSDDHCR peptide found inside the second cysteine-rich region, ELGQVVEC//
SLDFGLVCR which was present in the four through seven cysteine-rich regions as a four
times repeat peptide and 4176AQAQ//PGVPLGELGQVVECSLDFGLVCR4202, which was
found in the last cysteine-rich domain. The other five cleavage sites were from the C-
terminal end (i.e. one from MUC11p15 region, one from unique region, one from vWFD
domain and two from vWFC domain) (table 4). The MS/MS spectra of all non-tryptic
cleavage products were supplied as supplementary data (supplementary data 2).
Two distinct proteolytic cleavage regions on salivary MUC5B—one cleavage in the D′
region and one in the D3 domain—and their importance have been previously proposed 20.
The cleavage described in D′ region is similar to those found in vWF protein 21 that cleaves
a fragment of the N-terminal region up to D′ domain and may represent an important step
for post-secretory processing. However, our coverage analysis on MUC5B indicates that the
entire N-terminal region, including the D1, D2, D′, and D3 domains can be isolated and
identified, to be part of a mature and fully glycosylated mucin suggesting the molecule is
physically intact. The other cleavage, in D3, cleavage determines structural differences
between soluble and insoluble MUC5B in saliva22. The non-tryptic cleavage sites we
identified in this portion of the N-terminal region might be putative sites for such cleavages
but this remains to be validated in future studies.
Peptide coverage analysis of MUC5AC
The MUC5AC apoprotein (Swiss-Prot # P98088) is about 496734 Da in Mw (the complete
genomic sequence for the central MD regions is not completely clear) and yields 197 tryptic
fragments after digestion. Of these, 138 peptides were identified from 22 different regions
(Table 2, supplementary data 1). The longest peptide identified was 48 amino acids long
with a Mw of 5008.54 Da. Of these detected tryptic peptides, 54 (77% coverage) were from
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the N terminus. All 64 (100%) tryptic peptides of at least six residues or longer were
identified from nine different cysteine-rich domains within the central MD regions. Out of a
total of 35 tryptic peptides in the C-terminus region, 20 (60% coverage) were identified. The
MD region, as so far described, consists of only 18 peptides, all of which are heavily
glycosylated. From a mass spectrometry recovery view, two peptides are larger than 5000
m/z and 76 fragments are between one and five residues long. There are 20 predicted tryptic
STP-rich peptides between the first five Cys-rich domains. These regions are found
upstream of the large MD region and are heavily glycosylated even though they have no
repeat sequences. There are three putative N-glycosylation sites at the N-terminus and seven
at the C-terminus. Two N-glycosylation sites after PNGase F deglycosylation were found,
both of which were from the C-terminal region. The
peptide 4431FANNTEGQCGTCTNDR4446 is from the vWFD4 domain while the
other, 4963TSLRNVTLHCTDGSSR4978 is located in the cysteine-knot region. As with
MUC5B, all possible predicted peptides inside the small cysteine-rich regions inside the
heavily glycosylated MD region were identified. Like MUC5B, all of the nine cysteine-rich
regions have one WXXW motif. The peptide CTWTTWFDVDFPSPGPHGGDK inside the
fifth Cyst region was identified and the five times repeated motif WTKW has the trypsin
cleavage site (WTK/W) of which the C-teminal part of the peptide was identified, but the N-
terminal side was unidentified. This is possibly due to the C-mannosylation and/or O-
glycosylation of the region. We have less coverage of the C-terminus of MUC5AC as
compared with MUC5B. This is perhaps due to more N- and/or sparsely O-glycosylated
sites or to other post-translational modifications available at that region. Overall, we have 40
percent coverage of the whole MUC5AC protein which can be up to 90 percent after
excluding the heavily glycosylated MD region, the predicted N- and sparsely O-glycosylated
peptides and the peptides beyond our detection limits. An ‘error tolerant’ analysis of
MUC5AC yielded 16 non-specific cleavage peptides. Of these, seven were from N-terminal
unique regions and were two from the TIL domain. Unlike MUC5B, no non-tryptic cleavage
was found inside D domains at the N-terminal region (table 4, supplementary data 2). We
also identified five different non-specific cleavage sites on two predicted tryptic peptides,
one from the C-terminal vWFD domain and the other from the N-glycosylation rich region.
Although a cleavage in the 4301GDPH4304 sequence of the C-terminal region of MUC5AC
mucin has been reported 23, we did not detect this particular cleavage.
Overall, the reason for the presence of an unexpectedly large quantity of non-tryptic
cleavage sites on gel forming mucins MUC5B and MUC5AC and the complexity behind it
is another mystery. Some of the non-tryptic cleavage sites are similar to chymotrypsin,
NTCB, LysC, ArgC, and Asp-N type cleavages; however, most of these cleavage sites are
non-specific in respect to any known cutting agents. As can be envisioned from figure 1, not
every proteolytic cleavage can break mucin into smaller pieces since they are essentially
held together by disulfide bonds throughout the molecule. Despite these cleavage sites on
their naked protein domains, it appears that the gel forming mucins maintain their integrity
and molecular composition as assessed by light scattering measurements (not shown) and
agarose gel western blotting (supplementary figure 1). In abnormal conditions such as
infection and inflammation, however, the number of cleavage sites may increase due to
increased protease activity, which is either coming from host or intruder cells, and the mucin
molecules can lose their integrity. Taken together, cleavages reported here could be a useful
reference data for studies that use in-vivo secretions. For instance, comparison of the
cleavages of mucins isolated from different sources (e.g. MUC5B from sputum, saliva, and
cervical mucus under normal and disease conditions) will help better understanding of the
functional significance of these cleavages and of the functional requirements of different
mucosal surfaces. This should be to be pursued and elucidated in future studies.
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Peptide coverage analysis of Membrane tethered mucins of airways
MUC20—MUC20 (Q8N307) is one of the smallest airway mucins. The expressed protein is
about 72 kDa in mass. It has about 42 tryptic cleavage sites available in total and from these
about three peptides may be identifiable in the protein sequences of the C-terminus region.
Only one peptide 667LSVASPEDLTDPR679 was detected and it is from the far C-terminal
region close to the transmembrane domain.
MUC4—The molecular weight and size of the MUC4 (Q99102) molecule largely depends
on the number of repeats of three tandem repeat regions in the MD regions of the N-terminal
part. Taking one repeat, the MUC4 core protein has a predicted monoisotopic mass of
231,305 Da; however, given the range of 145–395 repeats in these regions, the actual varies
from 5 to 15 MDa. Of a potential 78 available tryptic peptides outside the heavily
glycosylated VNTR region, 32 peptides were identified from seven different domains of the
C terminus region. Of these, 14 are from the unique sequence (CT2 and CT8) regions, ten
from the cysteine-rich (CT3 and CT6) region, three from the vWD domain region (CT4),
two from the N-glycosylation rich region (CT5) and three from the EGF2 domain (CT-9)
(table 3, supplementary data 1). No extra peptide was found after PNGaseF treatment even
though MUC4 has more than ten putative N-glycosylation sites mostly in the N-
glycosylation region (CT5). Up to 35 percent coverage of the C terminus region was
achieved and after subtracting the predicted N-glycosylation and technically unavailable
peptides, that coverage ratio increased to up to 62 percent. Like MUC5AC, MUC4 also has
a 1443GDPH1446 cleavage site inside the vWFD domain though we could not identify the
cleavage product. On the other hand, two non-specific non-tryptic cleavage sites were
detected from the vWFD region, 1501SSSL//1505GPVTVQWLLEPHDAIR
and 1501SSSLG//1506PVTVQWLLEPHDAIR (table 4). The MUC4 gene can generate up to
24 splice variants by alternative use of exons. Consequently, a question arises regarding the
splice variants we have in our samples. According to our gel chromatographic and/or
agarose gel electrophoresis experiments, we have identified only the mature glycosylated
molecule in our cell culture mucus samples (supplementary figure 1). Evidence from the
coverage mapping from five different CT regions suggests this material is the sv0 form of
MUC4 with no splicing24.
MUC1 and MUC16—The C-terminal extracellular regions of MUC1 and MUC16 are
relatively simple in comparison to those of MUC4. The extracellular region of MUC1
protein consists of an O-glycosylation rich VNTR sequence and a SEA (Sea urchin sperm
protein, Enterokinase and Agrin) domain region. The membrane region of the protein
contains transmembrane and cytoplasmic domains. The MUC1 protein (P15941) has a
monoisotopic mass of 122,220 and yields only 19 tryptic peptides including one large
VNTR residue (929 amino acids long and serine and threonine-rich) with no cleavage site.
This region is followed by three sparsely glycosylated peptides, one of which exceeds 6000
m/z in mass, after which there is a SEA domain. There are only five identifiable peptides in
this region of which we identified three; the other two, 1090FRPGSVVVQLTLAFR1108
and 1156TEAASR1161, were not detected (table 3, supplementary data 1). The first of these
sites contains a known FRPG//SVVV cleavage site 25 which may explain its absence. A
large predicted N-glycosylated peptide (5961 m/z) follows the sequence, and the entire
transmembrane part of the molecule is present. The last part of the molecule is the
cytoplasmic tail and contains five tryptic peptides. Interestingly, we identified all five
peptides covering 100% of this cytoplasmic region which is consistent with the absence of
post-translational modifications. As we have previously described, we know that MUC1 is
found on some populations of exosome-like vesicles26. Therefore, it is not surprising that we
find its cytoplasmic domain. We also have evidence of non-tryptic cleavage sites inside the
cytoplasmic domain, DTYHPMS//1208EYPTYHTHGR1217, MSEY//1210PTYHTHGR and
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YV//1220PPSSTDR1226 (table 4). The cytoplasmic domain of MUC1 is a target for several
kinases 27 and is involved in a number of active processes in the cell. The three non-specific
cleavages are next to two putative phosphorylation sites by ZAP-70 and PKC gamma 27.
The functional significance of these cleavages inside the cytoplasmic domain is not clear;
however, given the role of CT domain in transcriptional activity of the molecule via nuclear
beta-catenin28, one speculation is that these cleavages in the CT domain may regulate the
transcription of the molecule.
MUC16 (Q8WXI7) is one of the largest expressed proteins in the genome with an expressed
apoprotein has over 22,000 amino acids and has a mass of around 2.3 Mda. The extracellular
repeat domain of the MUC16 molecule contains up to 60 tandem repeats of 156 amino acid
long repeats 29. A large proportion of the apoprotein, the first 12,000 amino acids, is the
threonine and serine rich region and is followed by a large SEA region that contains over
120 small SEA domains (about 120 amino acids each) (Table 3, supplementary data 1).
Over 100 of the peptides we found—virtually all of the peptides we identified—were from
this repeat region. In this region, some 15 peptides repeat two to ten times, while 32 other
peptides cover 30 percent of the repeat region. However, unlike any of the other mucins
studied, three peptides, 5131EIFPSINTEETNVK5144, 6402AFTAATTEVSR6412
and 7578VSTGATTEVSR7588, were clearly identified within the serine/threonine rich
glycosylated domain (Table 3, supplementary data 1). We have 50 percent coverage of the
repeat region. Though MUC16 has about 300 putative N-glycosylation sites, we found only
two N-glycosylated repetitive peptides after PNGase F treatment,
LYWELSNLTNGIQELGPYTLDR and NTSVGLLYSGCR, suggesting most of the N-
glycosylated regions were also O-glycosylated as well. The last portion of its C-terminal
cytoplasmic domain, 22152EGEYNVQQQCPGYYQSHLDLEDLQ22175 was also clearly
detected. Two repetitive non-tryptic cleavages were detected inside the SEA region
SEKDGA//ATGVDAICTHR and LYWE//LSQLTHGIKELGPYTLDR. The GSVVV motif
inside the SEA domains of membrane mucins, such as MUC1, MUC3 and MUC12, is the
site for the cleavage of these molecules to release the N-terminal region to the mucus layer
above 3031. However, MUC16 has no such motif over its SEA region and no cleavage sites
for MUC16 have been identified. The non-tryptic cleavages over the SEA region we
presented here may be the potential cleavage sites for such a function.
In conclusion, we report here the most exhaustive proteome analysis of the major mucins
released in the airways. The mucins described here are complex in both chemical structure
and architecture. Not only do they have extended carbohydrate rich domains but also large
unglycosylated and/or sparsely glycosylated protein rich regions that have definable tertiary
structures. It is quite possible that much of this complexity is associated with specific
biological functions such as binding other proteins, bacteria, viruses or other particulates or
with locating specific protective proteins in the surface epithelium, but all of this is as yet
undescribed in detail. This peptide coverage mapping of different domains and regions of
the mucins gives us useful general information on their peptide accessibility, cleavage sites,
post-translational modifications, and structure/function relationships. An important value of
this information to us has been to understand the post-secretory destiny of gel forming
mucins of the airways, MUC5B and MUC5AC, and to raise effective peptide antibodies for
fully glycosylated transmembrane mucins, e.g. MUC4 and MUC20, whereas previously,
only C-terminal cleavage sequences or non-glycosylated immature intracellular apoprotein
could be experimentally identified. Unidentified peptides/regions outside the MD regions
and the putative cleavage sites form an interest for our future studies related to post-
secretory mucin maturation/processing and to identification and characterization of the post-
translational modifications, and interaction sites for binding to one other and to other
proteins available in the same environment. Understanding the complex multi domain
structure of these huge gene products will also help to elucidate how these giant molecules
Cao et al. Page 9













contribute to the airway’s innate defense and to the progression of chronic airway diseases
and will eventually help in designing better therapeutic modalities targeting the airway
mucus.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Illustration of the regions of MUC5B (AC) accessible/inaccessible to proteolysis and
possible cleavages
A)- An electron microscopy image of a typical linear MUC5B (AC) molecule with a typical
structural domain representation of the MUC5B subunit on the top panel. The mucin sample
was isolated, prepared, and observed in an electron microscopy as described previously in
detail 32. The MUC5B (AC) molecule is assembled from multiple large subunits via
disulfide bond (S-S) mediated dimerization between COOH-terminal (C-) domains of
monomers to form dimers and subsequent oligomerization via NH2-terminal (N-) domains
to form higher oligomers. The mucin was traced with color-coded lines for individual
subunit in A′. The assignment of the structure as a monomer (yellow trace) is made on the
basis of the length (~400–600 nm). The N-N terminal region and C-C terminal region can
be delineated by their size. Scale bar, 50 nm.
B)- Naked N- and C- terminal protein regions where the molecule makes oligomerisation,
are susceptible to proteolysis (blue arrows). Although the cystein rich regions (Cys-) are
located inside the highly glycosylated mucin domains, they are also targets for proteases.
Despite these cleavage sites, mucin is still intact in normal conditions because they are held
together by disulfide bonds
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Table 4
List of non-specific cleavage peptides detected by mass spectrometry after MASCOT “error tolerant” database
search. The fragments are colored in red. The MS/MS spectra of all of these peptides are supplied at
supplementary data 2.
Mucin Cleavage site Domain Comment Digest #
MUC5B FP/GLCNYVFSEHCR; vWFD1 non-specific cleavage 1,2,3
YANQTCGL/CGDFNGLPAFNEFYAHNAR; vWFD1 Putative N-glycosylation at
the downstream non-




YANQTCGLCGDFNGL/PAFNEFYAHNAR; vWFD1 Putative N-glycosylation at
the downstream
3
FAECH/ALVDSTAYLAACAQDLCR; N-terminal unique non-specific cleavage 1,2,3
ALVDST/AYLAACAQDLCR; N-terminal unique non-specific cleavage 1,2,3,
ALVDST AY/LAACAQDLCR; N-terminal unique non-specific cleavage 1,
T/CPLNMQHQECGSPCTDTCSNPQR; N-Terminal TIL non-specific cleavage 1,2,3,
QADDFTAL/SGVVEATGAAFANTWK; vWFD2 Chymotrypsin type cleavage 1,2
NSFED/PCSLSVENENYAR; N-terminal unique non-specific cleavage 1,2,3
SFV/PVDGCTCPAG; N-terminal unique non-specific cleavage 2
CHSIINPK/PFHSNCMFDTCNCER; N-terminal unique LysC type cleavage 1,2,3
VCGL/CGNFDDNAINDFATR vWFD3 Chymotrypsin type cleavage 1,2,3
SV/VGDALEFGNSWK; N-termimal MUC11p15 non-specific cleavage 1
FCTAVAAYAQ/ACHDAGLCVSWR N-terminal unique non-specific cleavage 1,2,3
NPSGH/CLVDLPGLEGCYPK; N-terminal unique non-specific cleavage
ENCQSCNCTPSGIQCAH/SLEACTCTYEDR; N-terminal unique non-specific cleavage 1,2,3
MPLEE/LGQQVDCDR; Cys-rich-1 non-specific cleavage 2,3
VL/CCSDDHCR; Cys-rich-2 Chymotrypsin type cleavage 1,3
ELGQVVEC/SLDFGLVCR; Cys-rich-4,5,6,7. non-specific cleavage 1,2,3
SEWLDY/SYPMPGPSGGDFDTYSNIR; Cys-rich-4,5,6,7. Chymotrypsin type cleavage 1,2,3
AGCHFY/AVCNQHCDIDR C-terminal MUC11p15 non-specific cleavage 1,3
AQAQ/PGVPLGELGQVVECSLDFGLVCR; Cyst-rich-7 non-specific cleavage 1,2
ECECICSMWGGSHY/STFDGTSYTFR vWFD4 Chymotrypsin type cleavage 1,2,3
SCVCDEGSVSVQCK/PLPCDAQGQPPPCNR/PGFVTVTRPR; vWFD4 non-specific cleavage 1
NLSLYLD/NHYCTASATAAAAR; vWFD4 Putative N-glycosylation at
the downstream Glu- C type
cleavage
3
DQILFNAH/MGICVQACPCVGPDGFPK; C-terminal unique non-specific cleavage 1,2,3
MUC5AC SP/CADTCSNQEHSR; N-Terminal TIL NTCB type cleavage 1,2,3
GSMI/PNGESVHDSGAICTCTHGK; N-terminal unique non-specific cleavage 1,2,3
SE/DCLCAALSSYVHACAAK; N terminal unique available also in MUC5B,
Glu- C type cleavage
1
PSL/RTIPVVR; N terminal unique Chymotrypsin type cleavage 2,3
WKLS/PSCPDALAPK; N terminal unique non-specific cleavage 1,2,3
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Mucin Cleavage site Domain Comment Digest #
KQCSIL/HGPTFAACHAHVEPAR; N terminal unique Chymotrypsin type cleavage 1,2,3
SYRPGAVV/PSDKNCQSCLCTER; N terminal unique non-specific cleavage 1,2,3
PGAVV/PVDGCICPK; N terminal unique non-specific cleavage 2,3
GLICLNKNQL/PPICYNYEIR; Cys-rich-2,4 Chymotrypsin type cleavage 1
KWFDV/DFPSPGPHGGDK; Cys-rich-3,5,6,7,8,9 non-specific cleavage 1,2,3
SI/ILEYHQDR; vWFD4 non-specific cleavage 1,2
LY/PAGSTIYR; C-terminal unique Chymotrypsin type cleavage 1,,3
FCPEGMTLF/STSAQVCVPTGCPR; C terminal unique Chymotrypsin type cleavage 1,2,3
AC/PPLSCSLDEAR; C-terminal unique non-specific cleavage 1,2,3
TVG/MDCQECTCEAATWTLTCRPK; C-terminal unique non-specific cleavage 2
TC/PRVEKPTCANGYPAVK; C-terminal unique non-specific cleavage 1,3
MUC4 SSSL/GPVTVQWLLEPHDAIR; SSSLG/PVTVQWLLEPHDAIR; vWFD (CT4) Chymotrypsin type cleavage 1,2
SL/EPFTLEILAR; SLE/PFTLEILAR; N-Glycosylation rich (CT5) Chymotrypsin type cleavage 1,2
MUC1 MSEY/PTYHTHGR; Intracellular non-specific cleavage 1,2,3
YV/PPSSTDR; Intracellular non-specific cleavage 2,3
DTYHPMS/EYPTYHTHGR; Intracellular non-specific cleavage 1,2
MUC16 SEKDGA/ATGVDAICTHR; SEA non-specific cleavage 1,2,3
LYWE/LSQLTH GIKELGPYTLDR; SEA Glu-C type cleavage 1,2
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